Schizophrenia Clinical Trial
— DOMINOOfficial title:
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in the Italian Clinical Practice: a Retrospective Cohort, Observational Study
Verified date | May 2017 |
Source | Otsuka Pharmaceutical Europe Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an observational, retrospective, non-interventional study that will include
schizophrenic patients who were initiated with aripiprazole once-monthly as per normal
clinical practice at least 6 months before the data collection starts (inclusion visit), and
is designed to evaluate demographic and clinical predictors of persistence with this
treatment.
Data from each patient will be collected after informed consent is signed (inclusion visit),
and will include retrospective information from the start of aripiprazole once-monthly
treatment initiation (index date) until the follow-up/inclusion visit (minimum of 6 months
after the index date). Data will be retrospectively collected from all visits occurring as
per clinical practice (usually once monthly).
Status | Completed |
Enrollment | 262 |
Est. completion date | July 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adult patients (age = 18 years at the time of aripiprazole once-monthly initiation) 2. Male or female 3. Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5), available at start of aripiprazole once-monthly treatment, and confirmed by the current investigator 4. Aripiprazole once-monthly initiation (at least 1 injection) according to the clinical practice, at least 6 months before the inclusion and on June 1st 2015 or at a later date (index date) 5. Aripiprazole once-monthly was the main antipsychotic at the time of treatment initiation 6. Willingness to participate in the study; subjects must give their written consent to participate Exclusion Criteria: 1. The patient has a psychiatric disorder other than schizophrenia as primary diagnosis 2. Participation in a clinical trial during the retrospective follow-up period. |
Country | Name | City | State |
---|---|---|---|
Italy | Centro Salute Mentale | Ancona | |
Italy | SPDC ASST Spedali Civili | Brescia | |
Italy | Azienda Ospedaliero-Universitaria di Cagliari | Cagliari | |
Italy | Policlinico "G. Rodolico" | Catania | |
Italy | Policlinico Mater Domini | Catanzaro | |
Italy | Azienda Ospedaliero-Universitaria Careggi | Firenze | |
Italy | Casa Di Cura Neuropsichiatrica Villa Von Siebenthal | Genzano di Roma | |
Italy | Ospedale Maria S.S. dello splendore | Giulianova | |
Italy | ASL Lecce | Lecce | |
Italy | ASST Grande Ospedale Metropolitano | Milano | |
Italy | Azienda Ospedaliera Fatebenefratelli e Oftalmico | Milano | |
Italy | Ospedale San Gerardo | Monza | |
Italy | SCDU Psichiatria. AOU San Luigi Gonzaga | Orbassano | |
Italy | Azienda Ospedaliera di Padova | Padova | |
Italy | Clinica Psichiatrica. Università di Palermo | Palermo | |
Italy | Università degli Studi di Perugia | Perugia | |
Italy | Centro di Salute Mentale | Pomezia | |
Italy | ASL Salerno | Pontecagnano | |
Italy | Azienda Ospedaliera Universitaria Senese | Siena | |
Italy | Azienda ULSS 9 Treviso | Treviso |
Lead Sponsor | Collaborator |
---|---|
Otsuka Pharmaceutical Europe Ltd |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Persistence (number of days) with aripiprazole once-monthly treatment | During the first 6 months after aripiprazole once-monthly initiation. | ||
Secondary | Description of aripiprazole once-monthly discontinuations and temporary interruptions and their reasons. | Through study completion, at least 6 months. | ||
Secondary | Description of health resource use related to schizophrenia (hospitalisations, outpatient visits, procedures, schizophrenia drugs) | Through study completion, at least 6 months. | ||
Secondary | Mean Clinical Global Impressions - Severity scale (CGI-S) changes | Through study completion, at least 6 months. | ||
Secondary | Characterization of the schizophrenia dimensions of the participating subjects according to the Lifetime Dimensions for Psychosis Scale (LDPS) questionnaire. | Only one time: at the end of each patient's follow-up, at least 6 months after aripiprazole once-monthly initiation | ||
Secondary | Characterization of the psychotic spectrum of the participating subjects according to Structured Clinical Interview for the Psychotic Spectrum (SCI-PSY) questionnaire. | Only one time: at the end of each patient's follow-up, at least 6 months after aripiprazole once-monthly initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |